An update on pharmacotherapy for the treatment of fibromyalgia
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Fibromyalgia is a syndrome characterized by chronic generalized pain in addition to different symptoms such as fatigue, sleep disturbances, stiffness, cognitive impairment, and psychological distress. Multidisciplinary treatment combining pharmacological and nonpharmacological therapies is advised. AREAS COVERED: Publications describing randomized controlled trials and long-term extension studies evaluating drug treatment for fibromyalgia were searched in PubMed and Scopus and included in this review. EXPERT OPINION: Different drugs are recommended for the treatment of fibromyalgia by different published guidelines, although only three of them have been approved for this indication by the US FDA, and none have been approved by the European Medicines Agency. According to the available evidence, pregabalin, duloxetine and milnacipran should be the drugs of choice for the treatment of this disease, followed by amitriptyline and cyclobenzaprine. Other drugs with at least one positive clinical trial include some selective serotonin reuptake inhibitors, moclobemide, pirlindole, gabapentin, tramadol, tropisetron, sodium oxybate and nabilone. None of the currently available drugs are fully effective against the whole spectrum of fibromyalgia symptoms, namely pain, fatigue, sleep disturbances and depression, among the most relevant symptoms. Combination therapy is an option that needs to be more thoroughly investigated in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The american college of rheumatology 1990 criteria for the classification of fibromyalgia
Wolfe, F., Smythe, H. A., Yunus, M. B., Bennett, R. M., Bombardier, C., Goldenberg, D. L., Tugwell, P., Campbell, S. M., Abeles, M., Clark, P., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330203 · Cited by 9,563
Fibromyalgia: A Clinical Review
Clauw, D. J. (2014) · JAMA · doi:10.1001/jama.2014.3266 · Cited by 1,674
Worldwide epidemiology of fibromyalgia
Queiroz, L. P. (2013) · Current Pain and Headache Reports · doi:10.1007/s11916-013-0356-5 · Cited by 826 · cited 1×
“7% and a 3:1 female-to-male ratio [3].”
EULAR evidence-based recommendations for the management of fibromyalgia syndrome
Carville, S. F., Arendt-Nielsen, S., Bliddal, H., Blotman, F., Branco, J. C., Buskila, D., Da Silva, J. A. P., Danneskiold-Samsøe, B., Dincer, F., Henriksson, C., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.071522 · Cited by 752
Arnold, L. M., Lu, Y., Crofford, L. J., Wohlreich, M., Detke, M. J., Iyengar, S., & Goldstein, D. J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20485 · Cited by 624 · cited 11×
“Duloxetine has been administered at dosages ranging from 30 to 120 mg/day.”
BackgroundResultInfluentialArnold, L. M., Rosen, A., Pritchett, Y. L., D'Souza, D. N., Goldstein, D. J., Iyengar, S., & Wernicke, J. F. (2005) · Pain · doi:10.1016/j.pain.2005.06.031 · Cited by 471 · cited 13×
“Without psychiatric comorbidity except MDD or GAD Drugs are ordered according to their mention in the text and studies listed by year of publication.”
InfluentialFitzcharles, M.-A., Ste-Marie, P. A., Goldenberg, D. L., Pereira, J. X., Abbey, S., Choinière, M., Ko, G., Moulin, D. E., Panopalis, P., Proulx, J., et al. (2013) · Pain Research and Management · doi:10.1155/2013/918216 · Cited by 409
Bennett, R. M., Kamin, M., Karim, R., & Rosenthal, N. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00116-5 · Cited by 403
Nabilone for the treatment of pain in fibromyalgia.
Skrabek, R. Q., Galimova, L., Ethans, K., & Perry, D. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.09.002 · Cited by 384 · cited 8×
“ACR: American college of rheumatology; ACU: Acupuncture; AER: Aerobic exercise; AMT: Amitriptyline; APAP: Acetaminophen; BDI-II: Beck depression inventory-II; BID: Twice daily; BMI: Body mass index; BPI-s: Brief pain inventory-severity; CBT: Cognitive-behavioral therapy; CFT: Cardiovascular fitness training; cm: Centi…”
BackgroundInfluentialRussell, J. I., Mease, P. J., Smith, T. R., Kajdasz, D. K., Wohlreich, M. M., Detke, M. J., Walker, D. J., Chappell, A. S., & Arnold, L. M. (2008) · Pain · doi:10.1016/j.pain.2008.02.024 · Cited by 367
Cited by
Nociplastic pain: towards an understanding of prevalent pain conditions
Fitzcharles, M.-A., Cohen, S. P., Clauw, D. J., Littlejohn, G., Usui, C., & Häuser, W. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00392-5 · Cited by 1,253
Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment
Sarzi-Puttini, P., Giorgi, V., Marotto, D., & Atzeni, F. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-00506-w · Cited by 793
Fibromyalgia: Pathogenesis, Mechanisms, Diagnosis and Treatment Options Update
Siracusa, R., Paola, R. D., Cuzzocrea, S., & Impellizzeri, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083891 · Cited by 659
Analgesic Mechanisms of Antidepressants for Neuropathic Pain
Obata, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112483 · Cited by 398
Fibromyalgia Pathogenesis and Treatment Options Update
Chinn, S., Caldwell, W., & Gritsenko, K. (2016) · Current Pain and Headache Reports · doi:10.1007/s11916-016-0556-x · Cited by 296
Metadata
- Authors
- Calandre, E. P., Rico-Villademoros, F., & Slim, M.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2015-05-22
- Volume
- 16
- Issue
- 9
- Pages
- 1347-1368
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2187025190
- Cited by
- 119
- References
- 19
- FWCI
- 8.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An update on pharmacotherapy for the treatment of fibromyalgia. https://app.cochat.ai/papers/10.1517/14656566.2015.1047343
- The paper
- Calandre, E. P., Rico-Villademoros, F., & Slim, M. (2015). An update on pharmacotherapy for the treatment of fibromyalgia. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.2015.1047343
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.